Mavacamten is a selective, reversible, allosteric cardiac myosin inhibitor. It is approved under the brand name Camzyos ® for the treatment of adults with symptomatic New York Heart Association class ...
Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...
Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) in the first study of a cardiac myosin inhibitor (CMI) in adolescents ...
Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical ...
Aficamten offers a new treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials SEQUOIA-HCM and MAPLE-HCM showed aficamten's efficacy in improving exercise ...
These poster presentations took place between 29 th August–1 st September 2025 as part of the European Society of Cardiology (ESC) Congress in conjunction with the World Congress of Cardiology (WCC) ...
Cytokinetics, Incorporated's (CYTK) shares surged 40.4% on Sept. 2, driven by positive results from a phase III study on cardiovascular candidate aficamten. On Aug. 30, Cytokinetics presented primary ...
Cytokinetics snapped a two-day losing streak on Tuesday, soaring 40.45 percent to close at $49.62 apiece as investors cheered promising results from its study of Aficamten, its drug candidate for the ...
Guideline Directed Indications and Consequences of Delayed AVR in Patients With Asymptomatic, Severe Aortic Stenosis: Results From the EARLY TAVR Trial Receive the the latest news, research, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback